COMMUNIQUÉS West-GlobeNewswire

Constant Therapy Health Launches Web Platform for Speech, Language, and Cognitive Therapy
11/08/2026
Gives convenient desktop and laptop access to Constant Therapy’s clinically-proven rehabilitation exercise programs LEXINGTON, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Constant Therapy Health, a leader in AI-powered [...]
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
11/08/2026
Conference call will be held today, Tuesday, August 11 at 9:00 am ET CARMEL, Ind., Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08/2026
~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK ® Demand Carried into Third Quarter 2026 as Field Sales [...]
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
11/08/2026
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational [...]
Modern Haus Dental's Dr. Kristy Lee Recognized as Top Dentist by Bethesda Magazine for Third Consecutive Year
11/08/2026
She has also been named a Top Dentist by Washingtonian Magazine for two consecutive years Modern Haus Dental's Dr. Kristy Lee Earns Third Consecutive Bethesda Magazine Title Chevy Chase, MARYLAND, Aug. 11, 2026 (GLOBE [...]
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
11/08/2026
Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of [...]
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
11/08/2026
BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11/08/2026
The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated [...]
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
11/08/2026
Boehringer Ingelheim announced today that it has acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been exploring the use of [...]
Transactions in connection with share buy-back program
11/08/2026
Company announcement no. 30 - 26 11 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Exor and Philips Extend Long-term Relationship Agreement
11/08/2026
August 11, 2026 Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Exor N.V. today announced that they have agreed to update their long-term relationship [...]
Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed
11/08/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed [...]
Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V
11/08/2026
Ad hoc announcement pursuant to Art. 53 LR The DEA states that dual orexin receptor antagonists “do not produce physical or psychological dependence” Lower schedule expected to enhance patient access in the US Allschwil [...]
NORTH Performance Launches Globally with Pre-Sales Site and Founding Athlete Co-Owner Roster
11/08/2026
Next-generation all-in-one performance supplement brand, built on a radical athlete co-ownership model, opens pre-sales ahead of September 2026 product launch DOVER, Del., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NORTH [...]
MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
11/08/2026
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
Solésence Reschedules Second Quarter 2026 Conference Call to August 19
11/08/2026
ROMEOVILLE, Ill., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company has [...]
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
10/08/2026
Q2 Revenue of $9.1 million Q2 Income from Continuing Operations of $0.3 million Q2 Thyroid volume year-over-year increase of 6% Q2 Thyroid revenue year-over-year increase of 9% Trailing twelve-month thyroid revenue of $ [...]
Essential Amino Acid Intake Draws Focus During GLP-1 Therapy as Oh!mino Targets Muscle Loss
10/08/2026
Seal Beach, CA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Oh!Nutrition, a California-based nutritional product development company, today announced Oh!mino® Muscle Synthesis Activator, an essential amino acid supplement [...]
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2 [...]

Pages